Scarica l'app Stockscreener
8.25
0.60%
-0.05
Dopo l'orario di chiusura:
8.15
-0.10
-1.21%
Precedente Chiudi:
$8.30
Aprire:
$8.15
Volume 24 ore:
875.84K
Relative Volume:
0.62
Capitalizzazione di mercato:
$815.50M
Reddito:
$84.28M
Utile/perdita netta:
$-171.30M
Rapporto P/E:
-4.7487
EPS:
-1.7373
Flusso di cassa netto:
$-171.21M
1 W Prestazione:
+0.12%
1M Prestazione:
-12.61%
6M Prestazione:
-15.73%
1 anno Prestazione:
-29.18%
Intervallo 1D:
$8.00
$8.405
Intervallo di 1 settimana:
$8.00
$9.106
Portata 52W:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.25 | 820.44M | 84.28M | -171.30M | -171.21M | -1.7373 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-04 | Ripresa | Roth Capital | Buy |
| 2025-09-04 | Iniziato | Roth Capital | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Will ARS Pharmaceuticals Inc stock recover after earnings2026 Buyback Activity & Real-Time Buy Zone Alerts - baoquankhu1.vn
Update Report: Can ARS Pharmaceuticals Inc sustain earnings growthBond Market & Community Verified Trade Signals - baoquankhu1.vn
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Bamco Inc. NY Boosts Stake in ARS Pharmaceuticals - National Today
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Casdin Capital LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Move: Can ARS Pharmaceuticals Inc stock outperform in a bear market2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn
Institution Moves: What analysts say about ARS Pharmaceuticals Inc stock2026 Major Catalysts & Technical Pattern Recognition Alerts - baoquankhu1.vn
Guidance Update: Is ARS Pharmaceuticals Inc a top pick in the sectorProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
ARS Pharmaceuticals, Inc. (SPRY) reports Q4 loss, beats revenue estimates - MSN
[ARS] CUMBERLAND PHARMACEUTICALS INC SEC Filing - Stock Titan
How (SPRY) Movements Inform Risk Allocation Models - Stock Traders Daily
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha
SPRY: Expanding neffy access, advancing urticaria trials, and strong global uptake drive future growth - TradingView
SPRY: Expanding neffy access and advancing urticaria trials drive growth, with strong global uptake - TradingView
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX) - The Globe and Mail
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - MSN
Leerink raises ARS Pharmaceuticals stock price target on sales expansion - Investing.com Australia
Leerink raises ARS Pharmaceuticals stock price target on sales expansion By Investing.com - Investing.com Canada
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises - Investing.com India
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises By Investing.com - Investing.com South Africa
ARS Pharmaceuticals (SPRY) Q3 Loss Of US$51 Million Tests Bullish Profitability Narrative - Sahm
ARS Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
ARS Pharmaceuticals Announces Strong 2025 Financial Results and neffy® Commercial Launch Progress, Highlights Global Approvals and Market Expansion - Minichart
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals (SPRY) Posts Q4 Loss of $0.42/Share as Revenue Jumps 332% YoY to $28.1M - AlphaStreet
ARS Pharmaceuticals outlines sales force expansion and digital strategy for neffy growth while maintaining SG&A in 2026 - MSN
SPRY: neffy’s needle-free nasal spray is transforming emergency allergy care and driving rapid market growth - TradingView
ARS Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategy for Neffy Commercialization 49 - Minichart
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® Commercialization - Investing News Network
ARS Pharmaceuticals earnings beat by $0.01, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ARS Pharmaceuticals, Inc. (SPRY) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
ARS Pharmaceuticals (NASDAQ:SPRY) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q4 Revenue $28.1M - marketscreener.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.39 Loss - marketscreener.com
ARS Pharmaceuticals Reports 2025 Results and neffy Growth - TipRanks
ARS Pharmaceuticals Inc (NASDAQ: SPRY) announces that the regulatory approval timeline for its nasal spray epinephrine product Neffy in Canada has been clarified. - Bitget
ARS Pharmaceuticals 2025 10-K: $84.3M Revenue, $(1.74) EPS - TradingView
ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales - TradingView
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - ChartMill
Aug Levels: Will ARS Pharmaceuticals Inc. stock recover after earningsEarnings Beat & Free Reliable Trade Execution Plans - baoquankhu1.vn
Exploring ARS Pharmaceuticals's Earnings Expectations - Benzinga
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earni - GuruFocus
ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY): Analyst Consensus Sees 214% Upside Potential - DirectorsTalk Interviews
Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock By Investing.com - Investing.com South Africa
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.20%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):